RxDoctor Payments Data

Wen Ray Hsu, MD

Internal Medicine · New York, NYNPI 1326135468

Payments from drug & device makers

$4,944in general payments, 2019–2025

Across 182 payments — averaging $27.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$900
  • AstraZeneca$875
  • GSK$861
  • Bayer$415
  • Merck$280
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$269
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$4,87799%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,944 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$102,149
Medicare patients
376
Services billed
786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin227$134,093
EliquisApixaban251$122,305
Trelegy ElliptaFluticasone/Umeclidin/Vilanter159$99,656
TrulicityDulaglutide68$69,707
FarxigaDapagliflozin Propanediol59$36,920
Lactulose84$34,647
OzempicSemaglutide19$30,519
KerendiaFinerenone45$30,353
Breo ElliptaFluticasone/Vilanterol69$27,844
MounjaroTirzepatide20$23,167
JanuviaSitagliptin Phosphate26$16,917
TradjentaLinagliptin41$15,048
VascepaIcosapent Ethyl77$12,876
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$11,547
Combivent RespimatIpratropium/Albuterol Sulfate25$11,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$232$160,226293 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$861$133,550244 claims
Lilly USA, LLCTrulicity, Mounjaro$900$92,87488 claims
AstraZenecaFarxiga, Symbicort, Crestor, Nexium$875$48,860108 claims
Novo NordiskOzempic$139$30,51919 claims
BayerKerendia$415$30,35345 claims
MerckJanuvia$280$16,91726 claims
NovartisEntresto$227$10,23420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →